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Abstract
Background: Women living in Africa experience the highest burden of cervical cancer. Research and investment to
improve vaccination, screening, and treatment efforts are critically needed. We systematically reviewed and
characterized recent research within a broader public health framework to organize and assess the range of cervical
cancer research in Africa.
Methods: We searched online databases and the Internet for published articles and cervical cancer reports in
African countries. Inclusion criteria included publication between 2004 and 2014, cervical cancer-related content
pertinent to one of the four public health categories (primary, secondary, tertiary prevention or quality of life), and
conducted in or specifically relevant to countries or regions within the African continent. The study design, geographic
region/country, focus of research, and key findings were documented for each eligible article and summarized to
illustrate the weight and research coverage in each area. Publications with more than one focus (e.g. secondary and
tertiary prevention) were categorized by the primary emphasis of the paper. Research specific to HIV-infected women
or focused on feasibility issues was delineated within each of the four public health categories.
Results: A total of 380 research articles/reports were included. The majority (54.6 %) of cervical cancer research in Africa
focused on secondary prevention (i.e., screening). The number of publication focusing on primary prevention (23.4 %),
particularly HPV vaccination, increased significantly in the past decade. Research regarding the treatment of precancerous
lesions and invasive cervical cancer is emerging (17.6 %), but infrastructure and feasibility challenges in many countries
have impeded efforts to provide and evaluate treatment. Studies assessing aspects of quality of life among women living
with cervical cancer are severely limited (4.1 %). Across all categories, 11.3 % of publications focused on cervical cancer
among HIV-infected women, while 17.1 % focused on aspects of feasibility for cervical cancer control efforts.
Conclusions: Cervical cancer research in African countries has increased steadily over the past decade, but more is
needed. Tertiary prevention (i.e. treatment of disease with effective medicine) and quality of life of cervical cancer
survivors are two severely under-researched areas. Similarly, there are several countries in Africa with little to no research
ever conducted on cervical cancer.
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Background
Cervical cancer is the second most common cancer among
women worldwide, with an estimated 528,000 new cases
and 266,000 deaths among women each year [1]. A dispro-
portionate number of these cases (85 %) and deaths (87 %)
occur among women living in low and middle income
countries [1]. Women living with HIV are at increased risk
of developing cervical cancer [2–4] and experience more
rapid progression of the disease [5–7]. Since 1993, cervical
cancer was classified as an AIDS-defining illness [8].
The World Health Organization (WHO) advocates a
comprehensive approach to cervical cancer prevention
and control to identify opportunities to deliver effective
interventions [9]. Cervical cancer-related research has
increased significantly over the past decade, representing
biomedical, behavioral, and policy level findings. Existing
review papers synthesize knowledge and advancements
for multiple areas of focus within the larger effort of cer-
vical cancer prevention and treatment, e.g., biomarkers
for cervical cancer [10, 11], HPV vaccination for young
adolescent women [12–15], and feasible approaches to
screen and treat adult women in low resource settings
[16–20]. The purpose of this systematic review is to as-
sess and characterize recent research within a broader
public health framework, utilizing well-known public
health terminology to organize and assess the range of
efforts to respond to cervical cancer. In this context,
these include: Primary Prevention (preventing the initial
onset of cervical cancer), Secondary Prevention (early
detection by screening and treatment of precancerous cer-
vical lesions), Tertiary Prevention (treatment of cervical
cancer to reduce morbidity and mortality), and Quality of
Life (post-treatment care or palliative care for those without
treatment options) among women in African countries.
Literature highlighting feasibility considerations (accessibil-
ity, affordability, health care infrastructure, and provider
training) and findings specific to HIV-infected women are
integrated as appropriate in each public health category.
Primary prevention
Vaccination is one of the most commonly used public
health strategies to reduce the risk of infection and
minimize the prevalence of the disease-causing agent
(HPV) in the environment. Nearly all cases (99.7 %) of
cervical cancer are caused by human papillomavirus
(HPV) [21], particularly types 16 and 18 which cause more
than two-thirds of all precancerous cervical lesions and
cervical cancers [22, 23]. HPV is one of the most common
sexually transmitted infections, with up to 75 % of sexually
active people estimated to be infected at some point dur-
ing their lives [24]. Fortunately, two vaccines are approved
for use. The bivalent vaccine protects against HPV types
16 and 18. The quadrivalent vaccine protects against HPV
types 16 and 18 and also types 6 and 11, which cause 90 %
of genital warts [25]. Since HPV infection often occurs
shortly after the onset of sexual activity (over 35 % of
women are infected within 2 years of initiating sexual ac-
tivity) [26–28], vaccination campaigns should target 9–13
year old youth, prior to sexual debut. The vaccines are
over 95 % effective at preventing HPV infection caused by
vaccine-type HPV when the full three course dose is given
over six months [29, 30]. Since 2014, the WHO recom-
mends a two-dose regimen for girls and boys aged 9–13
(quadrivalent vaccine) or aged 9–14 (bivalent vaccine)
[31], which is not yet licensed in all countries, but reduces
the follow-up burden while maintaining strong protective
coverage [32–35].
The WHO recommends the inclusion of HPV vaccin-
ation in national immunization programs provided HPV
represents a public health priority and vaccine delivery is
feasible and cost-effective [31]. Unfortunately, HPV vaccin-
ation is not yet available in many African countries. By
August 2014, only 58 countries had introduced HPV vac-
cination for girls into their national immunization program
[31]. While the majority of these are high-resource
countries, a few low to middle income countries in Africa
including Rwanda, South Africa, Lesotho, and Uganda [36]
have also introduced national HPV vaccines. In 2013, the
Global Alliance for Vaccines and Immunizations (GAVI)
began providing support for HPV vaccinations to eligible
countries and will support demonstration projects in 23
countries, of which ten have been launched, primarily in
sub-Saharan Africa [37, 38]. However, barriers to vaccin-
ation (i.e. concerns about the safety of the vaccine, provider
reservations about recommending vaccination for younger
girls, limited awareness of the relationship between HPV
and cervical cancer, and varied parental acceptance of the
HPV vaccine [39–42]) result in inconsistent vaccine uptake,
globally [13, 43]. Recent efforts to vaccinate young boys
have received less focus, but may help indirectly protect
girls by reducing the risk of re-infection with HPV and will
help prevent other HPV-related morbidities for men in-
cluding penile cancer, anal cancer, oropharyngeal cancer,
and genital warts [44].
Other primary prevention strategies to reduce HPV in-
fection and cervical cancer include delaying sexual debut,
reducing the number of lifetime sexual partners, and in-
creasing condom use [45]. In addition to reducing HIV ac-
quisition and transmission, medical male circumcision is
also protective for HPV in males [46–48], which reduces
the risk of initial or re-infection of HPV among women.
Secondary prevention
Screening for early detection and treatment is a corner-
stone of secondary prevention. Early diagnosis and treat-
ment of cervical pre-cancerous lesions prevents up to
80 % of cervical cancers in high resource countries
where cervical cancer screening is routine [49]. In higher
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income countries, cervical cytology (Pap smear) in which
cervical cells are examined in order to detect cervical
intraepithelial neoplasia (CIN) became part of routine
care in the 1940’s [50]. For women who screen positive
for premalignant cervical lesions (i.e., CIN), a confirma-
tory colposcopy is required [51]. Cervical cytology, how-
ever, is not a feasible method of screening in many
African countries given the required level of medical and
laboratory infrastructure and trained personnel, multiple
return visits with poor patient tracking strategies, and
availability of such services often limited to capital cities.
The proportion of women in sub Saharan Africa reporting
a pelvic exam and pap test in the previous three years is
very low (1.0 % in Ethiopia to 23.2 % in South Africa), with
40 % of women in Tunisia to 94 % of women in Malawi
having never received a pelvic exam [52, 53].
The more feasible, and WHO-approved, strategy for
cervical cancer screening in low resource settings is visual
inspection with acetic acid (VIA) or visual inspection with
Lugol’s iodine (VILI). After applying acetic acid or Lugol’s
iodine directly on the cervix, pre-cancerous and cancerous
lesions turn white, making them visible to the naked eye
[54]. This method has high sensitivity among HIV-
infected and uninfected women [55, 56]. Results are
immediate, thus women who screen positive for precan-
cerous lesions can theoretically be offered cryotherapy
treatment during the same visit, or a “screen and treat”
approach, if the health facility has the capacity. This strat-
egy has been shown cost-effective, affordable, and an ideal
first-line treatment for CIN of any grade when the cervical
lesion size and location allows the cryoprobe tip to make
adequate contact [57–60]. This ‘screen and treat’ strategy
can avoid the burden of costly follow up visits, significant
delays in treatment, and loss to follow up [61, 62].
Cryotherapy can be performed at the primary care level
by mid-level providers, such as nurses or midwives, who
can be trained to perform cryotherapy with a minimum of
supplies and equipment [58, 63]. In developed countries,
cryotherapy is approximately 90 % effective for all grades
of CIN after 1 year [64]. The most commonly employed
treatment options for pre-cancerous lesions are removal
of diseased tissue using loop electrosurgical excision pro-
cedure (LEEP) which requires local anesthetic [65, 66] or
by freezing the affected tissue with cryotherapy [57].
These treatments are typically performed by trained pro-
viders in outpatient clinics at provincial or referral level
hospitals. Cold-knife conization [65] can be used to re-
move lesions that cannot be effectively treated with LEEP
or cryotherapy.
The optimal frequency of screening is every 3–5 years
depending on screening method [67], or within 3 years
for women living with HIV [68]. If a woman can be
screened only once in her lifetime, the most strategic
age is between 30 and 39 years [69]. Recent estimates on
national rates of cervical cancer screening are not avail-
able for many African countries, but a number of studies
report self-reported screening rates to be low (8.3–64 %)
[70–74], but slightly higher among women accessing
HIV-care (9.4–80 %) [72, 75, 76]. A 2008 population-
based survey in 57 countries estimated 19 % of women
in developing countries were screened for cervical
cancer in the preceding three years [77]. In addition to
infrastructure and resource-related barriers, awareness
of cervical cancer among reproductive-aged women re-
mains low [70, 78–81] and an inadequate proportion of
health care providers has been trained to provide high
quality screening [82, 83]. Efforts have been made in
many countries to integrate cervical cancer screening in
HIV care, but routine provision is still limited [77, 84].
HPV DNA testing represents an emerging strategy for
early detection of cervical cancer, particularly if technol-
ogy innovations can permit point-of-care testing which
will eliminate requirements for laboratory infrastructure
and technical support [68, 85]. HPV DNA testing must be
made affordable for widespread use in African countries.
Tertiary prevention
Women with abnormal cervical tissue are diagnosed with
either precancerous lesions or invasive cervical cancer,
both of which require treatment. Severe cervical dysplasia
that remains undiagnosed or untreated can develop into
invasive cancer [86]. Unfortunately, a significant propor-
tion of women (56–80.6 %) [(Kenya) [87]; (Tanzania) [88];
(Nigeria) [89]) are identified once their cervical cancer is
at an advanced stage [90].
Staging the severity of invasive cervical cancer requires
assessment of the vagina, parametrium, urinary bladder
and rectum by a combination of clinical and endoscopic
procedures to determine the stage of progression (I – IVB)
[91]. Inadequate laboratory facilities and personnel short-
ages may result in treatment decisions being made without
proper diagnoses or adequate information. Treatments for
invasive cervical cancer can include a range and combin-
ation of strategies including hysterectomy (requires surgical
facilities), radiotherapy (external and intracavitary radio-
therapy infrastructure), and chemotherapy [68, 92, 93]. The
availability of these options are typically limited to capital
cities in several African countries or, in some cases, not
available at all [94]. Consequently, palliative care with
symptom control and support may be the most likely op-
tion for severely late stage cervical cancer or for women
with less advanced disease, but who cannot afford or access
treatment. Studies indicate that only between 24–67 % of
those diagnosed with cervical cancer in Tanzania,
Zimbabwe, Uganda or Nigeria received some form of treat-
ment (either radiotherapy or hysterectomy) [88, 89, 95, 96],
with women in advanced stages (III and IV) of disease
Finocchario-Kessler et al. BMC Women's Health  (2016) 16:29 Page 3 of 25
progression [96] and women co-infected with HIV [88] less
likely to be treated.
Cervical cancer mortality rates in low resource countries
are nearly three times as high as rates experienced in high
resource settings [1, 97, 98]. Survival data for cervical can-
cer in African countries are limited. Estimated 5-year sur-
vival for women diagnosed with cervical cancer in 7
African countries between 2005 – 2009 was 56.3 % (range
19.5–96 %) [99]. Among women receiving treatment
(radiotherapy and/or surgery), survival probabilities at one
year post diagnosis ranged from 73.9–90.4 % and de-
creased progressively to 32.5 % by four years [87, 95, 96,
100]. Without treatment, observed survival is 58.6 at 1 year
and decreases to 31.1 % by 4 years [95, 96]. Studies from
Uganda and Zimbabwe suggest that although treatment
with radiotherapy improves patient survival two to three
years after diagnosis, this advantage disappears in later
years [95, 96].
Quality of life
Cervical cancer is associated with psychological and
physical morbidities that negatively impact quality of life
[101, 102]. Age-adjusted, daily-adjusted life years
(DALY) lost from cancer in African countries is consist-
ently higher than those of high resource countries [103].
The estimated DALY lost from cervical cancer in sub-
Saharan Africa is 641 years per 100,000 women [103].
Quality of life is most compromised among patients with
inoperable cervical cancer treated by radiotherapy, with
a majority reporting deterioration in physical, emotional,
social, and economic support [104], and the highest risk
for long-term dysfunction of bladder, bowels and
psychosocial consequences [105]. Other treatment re-
lated side-effects such as extended vaginal bleeding and
chronic radiation enteritis can affect physical and social
aspects of their quality of life [106, 107].
Significant changes in the sexual domain resulting in
marital discordance [104] and waning partner support
over the course of treatment and survival [108] have
been reported in Kenya and South Africa. While such
data are limited for low-resource settings, literature
reviews from high resource countries document post-
treatment changes in body image, vaginal function,
sexual satisfaction, and sexual relationship with partner;
indicating a clear need for better integration of sexuality
rehabilitation into routine clinical care [109–111]. Fur-
thermore, there are few treatment options available that
preserve fertility [92, 112–114], which can have signifi-
cant implications for young women given the personal
and cultural importance of childbearing [115]. Open
communication about fertility and sexuality-related is-
sues with cervical cancer patients of reproductive-age
should occur prior to treatments to help shape expecta-
tions and quality of life during recovery [113].
In most African countries, there is a long historical
precedent of providing palliative care at home by family
or community members [116]. Although strengthened
by the AIDS response, palliative care efforts still fail to
provide effective pain relief [91], with the availability and
accessibility of opioids for pain relief severely limited in
African countries [117]. In a study among Nigerian
cancer patients (including cervical cancer patients), the
presence of pain was significantly associated with de-
pressive and anxiety symptoms, suicidal ideation, poor
sleep, impaired concentration, lack of opportunity for
leisure, dissatisfaction with health, poor overall quality of
life, poor ability to get around and the need for excessive
medical treatment to function in daily life [118]. In 2011,
only four African countries had integrated palliative care
into their cancer strategic plans and two others had
stand-alone national palliative care policies [119]. Pain
management for cancer patients should not be neglected
as countries develop and adapt their response to cervical
and other cancers.
Feasibility considerations
Governments grapple with challenges posed by limited
funds and competing healthcare priorities including a
heavy burden from both infectious and chronic diseases.
While the African Cancer Registry Network (AFCRN),
launched in 2012, supports 25 cancer registries in 19
member countries in sub Saharan Africa [120, 121], many
still lack established cancer prevention and control health
policies [94, 122]. The geographic distribution of cancer
treatment centers with cytology laboratories, radiotherapy
and chemotherapy infrastructure severely limits accessibil-
ity for residents in more rural areas [49, 54, 85]. A 2009
situational analysis of east, central, and southern African
countries estimated that only 4 % of institutions had
equipment to perform outpatient treatment modalities
such as cryosurgery [123]. This demand for scarce services
typically results in long waiting periods (median
3.8 months in Ethiopia [100]) for treatment. The costs for
return hospital visits, pathology reports, and subsequent
treatment are beyond the resources of the majority of
women in these settings [124]. According to a recent
study, infrastructure investment of approximately $59
million would be required to equip every cervical cancer
screening facility with cryotherapy equipment in 23 high-
incidence sub-Saharan African countries [125] to be able
to employ the recommended screen and treat approach
[51]. Estimating the ability to screen nearly 20 million
women over a 10 year period in these targeted countries,
the costs for screening (VIA) would be less than $10 USD
per woman, and the costs for treatment by cryotherapy or
LEEP would range between $38 to $71 USD per woman
[125]. Systems to track and refer women who test positive
and support treatment retention are also lacking;
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diminishing the return on investment of current screening
efforts.
Methods
We searched several online databases including PubMed/
MEDLINE (NCBI), Embase (Elsevier), African Index
Medicus (AIM), and Google Scholar for published studies.
Our search also included highly relevant global and gov-
ernment reports not published in peer-reviewed journals.
Inclusion criteria included publication between 2004 and
2014, cervical cancer-related content pertinent to one of
the four public health categories (primary, secondary, ter-
tiary prevention or quality of life), and conducted in or
specifically relevant to countries or regions within the
African continent. Reference sections of articles were
reviewed to identify additional eligible articles. Searches
for each of the four focus areas were conducted separately,
including combinations of the following search words: 1)
primary prevention [HPV vaccination, Africa, cervical
cancer prevention, HPV prevention, cost effectiveness, med-
ical male circumcision, coverage], 2) secondary prevention
[cervical cancer screening, Africa, cervical cancer second-
ary prevention, HPV screening, screen and treat, male
HPV screening], 3) tertiary prevention [cervical cancer
treatment, Africa, SSA, pre-cancerous lesions, invasive
cervical cancer, management of invasive cervical cancer in
Africa, cervical cancer survival, HIV, access to treatment,
challenges,], and 4) quality of life [cervical cancer, quality
of life, Africa, sexual function, palliative care, relationship
challenges, partner support, treatment recovery]. A separ-
ate search was conducted to identify research focused on
issues of feasibility and infrastructure [health care infra-
structure for cervical cancer, Africa, accessibility, afford-
ability, training health care providers, provider knowledge,
feasibility, HPV vaccine, screening, screen and treat, treat-
ment]. Rather than creating a section dedicated to feasibil-
ity issues, these were integrated into the preceding
categories, depending on the focus of the article.
The study design, geographic region/country, focus of
research, and key findings were documented for each eli-
gible article. Articles and reports were maintained in
four separate spreadsheets (reflecting the four priority
categories) and later combined to review and eliminate
any duplication and to determine the best grouping for
articles that may have covered more than one primary
category. The articles and reports under each primary
category were then analyzed and refined to highlight
sub-themes, type of literature (original research, review
article, lessons learned or policy paper) and the country
or geographic region of research, Tables 1, 2, 3 and 4.
One thousand five hundred six records were reviewed
through database and Internet searches (Fig. 1). Among
those 389 met the criteria for inclusion. After eliminating
nine duplicates among the categories, a total of 380 records
were included in this review. Publications have been orga-
nized according to four targeted categories of public health
interest to illustrate the weight and coverage of research in
each area. Publications that span more than one area of
focus (e.g. secondary and tertiary prevention) were catego-
rized by the primary emphasis of the paper.
This systematic review did not require approval from
an ethical review board or informed consent with partic-
ipants as research efforts were limited to the review and
analysis of previously published or presented cervical
cancer research in African countries.
Results
Primary prevention
Table 1 reports the predominate focus of each article de-
scribing primary prevention. Of all 89 publications identi-
fied, 76 (85 %) focused on the HPV vaccination for the
prevention of HPV/cervical cancer. Only 13 (15 %) focused
on other prevention methods (mainly male circumcision
but also condom use and microbicides), of which eight
were performed in Uganda by the same study group. We
could not find any study that examined the prevention of
HPV and/or cervical cancer by delayed sexual debut, ab-
stinence, and/or limiting the number of sexual partners.
Considering the multiple foci of each paper, rather than just
the primary focus, 17 talked about the cost-effectiveness or
estimated impact of HPV vaccinations; 40 had a focus on
acceptability, knowledge, and/or attitudes [12, 39–41, 126–
152]; ten had a focus on uptake and/or retention [43, 152–
160]; five had a focus on populations affected by HIV [47,
161–163]; four had a focus on males [132, 138, 150, 158];
four had a focus on safety and immunogenicity [161, 162,
164, 165]; one on adverse events [166]; and three on policy
[167–169]; ten on male circumcision [46–48, 170–176];
two on lubricants, gels, and/or microbicides [177, 178], one
on diaphragms [177]; and one on condoms [179].
Of the 76 publications about HPV vaccination, the re-
searchers and/or study received some support from the
Fig. 1 PRISMA flow diagram of the number of searches yielded,
excluded, and reviewed
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Table 1 Primary Prevention Research, n = 89





25 Original research [39–41, 126, 127,
130–132, 134–137, 139, 144–151, 158,
180, 256, 257]
2 Review Articles [12, 15]
0 Lessons Learned
2 Policy Papers [167, 258]
Tanzania [126, 180], Uganda [40, 127], Nigeria [131, 137, 256],
South Africa [130, 139, 148, 150, 151, 158], Malawi [41],
Mali [132, 147], Cameroon [134, 144], Kenya [39, 145, 257],
Botswana [135], Ghana [136], Zambia [146], Morocco [149]
Uptake/Retention (N = 10) 6 Original research [43, 153, 155, 157, 159,
160]
1 Review Articles [259]
3 Lessons Learned [154, 156, 260]
0 Policy
Uganda [153, 259, 261], Lesotho [43, 155], Cameroon [43, 155,
156], Tanzania [155, 160], Uganda [155, 157], Kenya [155],
South Africa [159], Rwanda [154, 260]
Feasibility (N = 23)
Cost/cost effectiveness [14, 170, 181, 214,
261–269]
Estimated impact [270–272]
Provider knowledge/training [128, 129, 133,
140–143]
21 Original research [128, 129, 133,
140–143, 170, 181, 214, 261, 263–272]
2 Review Articles [14, 262]
0 Lessons Learned
0 Policy
Tanzania [14, 181, 267, 269], Uganda [14, 267, 271],
Sub-Saharan Africa [262, 264], Mali [263, 270], Nigeria [128,
140, 141, 143, 265], South Africa [129, 142, 214], GAVI-eligible
countries [266, 268, 272], Kenya [267, 271], Mozambique [271],
Zimbabwe [271], Guinea [170], Cameroon [133]




South Africa [161, 162]





Other (N = 11)
Safety/Immunogenicity (n = 2) [164, 165]
Adverse Events (n = 1) [166], Barriers (n = 1) [42],
Policy (n = 6) [168, 169, 273–276], Conference
Summary (n = 1) [152]
3 Original research [164–166]
2 Review Articles [42, 152]
0 Lessons Learned
6 Policy [168, 169, 273–276]
Uganda [166, 168, 274], Senegal [164], Tanzania [164, 165],
Low-Middle Income Countries [42, 273, 276], Middle East/
North Africa [275], Sub-Saharan Africa [152, 169]






South Africa 12, Uganda 12, Tanzania 10, Nigeria 8, Cameroon
6, Kenya 6, Mali 4, Low-Middle Income Countries 3, GAVI
Eligible Countries 3, Lesotho 2, Rwanda 2, sub-Saharan Africa
4, Malawi 1, Botswana 1, Ghana 1, Zambia 1, Morocco 1, Ivory
Coast 1, Mozambique 1, Zimbabwe 1, Middle East/North
Africa 1, Guinea 1
Non-Vaccine
Prevention




Uganda [47, 48, 171–174, 176, 277], South Africa [46, 175]

















Table 1 Primary Prevention Research, n = 89 (Continued)
0 Lessons Learned
0 Policy
Lubricant Gel, Microbicides and/or Diaphragm
(N = 2)




South Africa [178], Zimbabwe [177]
Primary Prevention (Non-Vaccine)
Total = 13















pharmaceutical companies that manufacture HPV vacci-
nations in 16 (21 %) of the studies [43, 126, 142, 153,
155–157, 160–162, 164–166, 170, 180, 181]. All studies
that looked at safety/immunogenicity of the vaccines in
HIV-infected [161, 162] and HIV-uninfected [164, 165]
women were funded by pharmaceutical companies.
Knowledge/awareness and acceptability of the HPV vac-
cine was often reported together and assessed in many dif-
ferent countries in SSA and among many different
populations. While acceptability of HPV vaccination tends
to be high, knowledge and awareness of the vaccination is
low, even amongst health care workers. There is a glaring
lack of literature regarding HPV vaccination among HIV-
positive populations and among males. Despite some data
indicating HPV’s role in other cancers (i.e. penile, anal,
throat and mouth), all vaccination programs have focused
solely on cervical cancer prevention. The few studies that
focused on males emphasized their ability to influence
HPV vaccine decision making in females or HPV vaccin-
ation in males to help protect females from cervical can-
cer. Direct benefits for men’s health (i.e. reductions in
genital warts, and penile, anal, throat/mouth cancers) were
not highlighted.
Geographically, South Africa and Uganda contributed
the most research, representing 18 and 23 % of all pri-
mary prevention articles, respectively, and were repre-
sented in both vaccination and non-vaccination articles.
Secondary prevention
We identified a significant number of publications (n =
208) focused on various aspects of secondary prevention
of cervical cancer. Table 2 reports the predominant focus
of each article. The primary focus of the 208 published ar-
ticles include: 46 (22 %) on screening test performance; 16
(8 %) on screen-and-treat program implementation and/
or outcomes; 28 (13 %) on screening feasibility including
infrastructure, provider knowledge and attitudes, and
costs; 59 (29 %) on women’s knowledge about, attitudes
towards, and uptake of cervical cancer; 18 (8 %) on cer-
vical cancer screening specifically among HIV+ women; 3
(1.5 %) on aspects of HPV/cervical cancer screening rele-
vant to males; 23 on program (excluding screen-and-treat
programs) or intervention implementation and/or out-
comes; and 15 focused on other categories. A total of 65
(32 %) reported on observed or self-reported uptake (ran-
ging between 0–100 %; mean = 25 %; median = 15 %)
among different populations.
VIA/VILI and HPV testing were the most commonly
evaluated screening tests, both individually and when
compared with other tests. Of the 15 articles examining
the performance of HPV testing, 12 compared different
sample collection methods (i.e. self vs. physician collected
samples [182–189]; dried cervical spots [190, 191]; tam-
pons [188, 191, 192]). Sensitivity and specificity of each
test ranged from 25–91.7 % [193, 194] and 64.6–98.2 %
[195, 196] for VIA, 44–97.7 % [194, 195] and 68.9–97.3 %
[196, 197] for VILI, 31–90.4 % [193, 195] and 84.5–96.9 %
[193, 198] for cytology, and 63.9–100 % [192, 198] and
73–96.6 % [184, 198] for HPV DNA testing, respectively.
The sensitivity and specificity of self-collected and
physician collected HPV samples were similar, making it
useful for women who may be reluctant to undergo a
pelvic exam.
Most (53 %) of the articles focusing on a screen-and-
treat approach assessed VIA/VILI and then treatment
with cryotherapy. While many reported on barriers, chal-
lenges, and lessons learned from this approach [199–202],
most indicated that screen-and-treat methods were safe,
acceptable, and feasible in African settings and reduced
loss-to-follow up after a positive screening test. One com-
mentary [203] was critical of screen-and-treat approaches,
stating a lack of evidence of safety which can compromise
acceptability and potential effectiveness of all screening
programs. Articles focusing on awareness and utilization
were mostly cross-sectional studies and reported low
levels of knowledge and awareness of cervical cancer
screening, but generally positive attitudes [204, 205]. This
was supported by higher uptake (59.6–100 %) of screening
among women who were offered the test as part of an
intervention [71, 75, 84, 206, 207].
The majority of articles in the feasibility section focused
on provider knowledge, awareness, and acceptability. Al-
though knowledge of cervical cancer and screening
methods was higher amongst health care workers com-
pared to the general population [208–211], utilization of
screening among female health care workers remained
low (4–41 %). Cervical cancer screening programs were
extremely cost-effective, either implemented by them-
selves [59, 212, 213] or in combination with other cervical
cancer prevention programs [214]. However, infrastruc-
ture challenges reported in both feasibility and program/
policy implementation articles (long travel distances to
screening and care centers, lack of gynecologists and la-
boratory pathologists and other manpower shortages,
equipment problems, poor record keeping, inadequate pa-
tient follow-up, and delayed testing results [215–220])
make wide scale implementation and utilization challen-
ging in many African settings.
Only three articles were identified that focused primar-
ily on males and cervical cancer screening in Africa
[221–223]. Similarly, while several articles included
HIV-positive women in their analyses [72, 224, 225],
only 16 focused exclusively on cervical cancer screening
among HIV-positive women. Despite a higher positivity
rate among HIV-infected women [224, 226], knowledge
of cervical cancer screening [75, 225, 227, 228] and up-
take [72, 75, 227, 228] is still low. Integrating HIV care
and cervical cancer screening [229–231] and utilizing
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Table 2 Secondary prevention research, n = 208
Primary focus Literature type Countries/Geographic Regions Included
Secondary
Prevention
Screening Test Performance (N = 46)
11 VIA/VILI [194, 196, 197, 232, 278–284]
15 HPV Testing [163, 182–192, 285–287]
3 Cytology [288–290]
1 Colposcopy [291]
16 Comparison of 2+ tests [16, 193, 195,
198, 292–303]
41 Original Research [182, 184–186, 188–198,
232, 278–293, 295, 296, 298–303]
4 Review Article [16, 187, 294, 297]
Lessons Learned
1 Policy Papers [163]
Africa (2) [285, 297], Developing Countries (4) [16, 284, 294,
302], Angola (1) [197], Botswana (1) [232], Burkina Faso (5)
[194, 280, 282, 291, 298], Cameroon (4) [182, 193, 286, 300],
Democratic Republic of Congo (3) [195, 198, 296], Republic
of the Congo (6) [191, 194, 280, 282, 291, 298], Egypt (2) [186,
278], Gambia (1) [192], Ghana (1) [288], Guinea (5) [194, 280,
282, 291, 298], Ivory Coast (1) [190], Kenya (2) [184, 301], Mali
(5) [194, 280, 282, 291, 298], Niger (5) [194, 280, 282, 291, 298],
Nigeria (4) [279, 287, 289, 293], Rwanda (1) [294], South Africa
(7) [163, 183, 187, 188, 290, 292, 299], Tanzania (2) [196, 295]
Screen-and-Treat (SNT) (N = 16)
8 VIA then Cryotherapy [63, 199–201,
304–307]
5 Other SNT methods [61, 308–311]
3 Guidelines/Overview [51, 202, 203]
10 Original Research [61, 63, 200, 201, 305,
307–311]
2 Review [203, 304]
2 Lessons Learned [199, 202]
2 Policy [51,283 1,217]
Global (1) [51], Africa (1) [203], Botswana (1) [307], Ghana (1)
[63], Kenya (1) [61], Madagascar (1) [306], Malawi (1) [306],
Nigeria (2) [306, 311],South Africa (2) [308, 310], Tanzania (1)
[306], Uganda (2) [200, 306], Zambia (7) [199, 201, 202,
304–306, 309]
Feasibility (N = 28)
2 Infrastructure [215, 220]
18 Provider Knowledge/Training/Attitudes
[60, 82, 83, 208–211, 312–322]
8 Cost/Cost-effectiveness [59, 125, 212–214,
323–325]
26 Original Research [59, 83, 125, 208–215,
220, 312–325]
2 Review [60, 82]
0 Lessons Learned
0 Policy
Africa (3) [82, 125, 212], Cameroon (1) [313], Ghana (1) [323],
Ivory Coast (1) [208], Kenya (2) [59, 325], Nigeria (11) [83, 211,
220, 312, 315–317, 319–321], South Africa (6) [59, 213, 214,
318, 324, 325], Tanzania (1) [209], LRC [60]
Awareness and Utilization (N = 59)
44 Knowledge, Attitudes, Uptake [53, 70, 72,
74, 78–80, 204–207, 225, 326–357]
15 Determinants of Uptake [62, 73, 358–370]





Global (1) [368], Developing Countries (1) [328], Botswana (3)
[72, 205, 349], Cameroon (1) [74], Ghana (2) [70, 326], Kenya
(5) [204, 335, 340, 355, 358], Malawi (1) [53], Mozambique (1)
[207], Morocco (1) [365], Nigeria (18) [78, 79, 225, 332–334,
337, 338, 342, 344–346, 348, 351, 352, 363, 366, 367], South
Africa (12) [80, 327, 329, 330, 341, 347, 353, 356, 360, 361, 369],
Sudan (1) [343], Tanzania (5) [62, 336, 362, 364, 370], Tunisia
(1) [331]
HIV-Positive Women (N = 18)
5 Service Integration [77, 84, 229–231]
9 Test Performance [371–379]
3 Knowledge, Attitudes, Uptake [75, 227, 228]
1 Screen-and-Treat [226]





Global (1) [231], Burkina Faso (1) [373], Cameroon (1) [230],
Kenya (4) [229, 374, 376, 378], Nigeria (3) [75, 84, 227], South
Africa (6) [226, 228, 371, 373, 375, 377], Uganda (1) [379],
Tanzania (1) [77]
Males and HPV Screening (N = 3)
1 Knowledge and Beliefs [221], 1 Male Partner
Support [222], 1 Penile HPV Detection [223]




Ghana (1) [221], Kenya (1) [223], Uganda (1) [222]
Other (N = 38)
23 Program/Policy Implementation [54, 71,
216–219, 224, 380–395]
3 Screening Follow-Up [396, 397] and
Side-effects [398]
5 Overview of Current Situation [123, 399–402]
7 Other Ethical Issues,[403] message development,
[404] overviews,[69, 85, 405, 406] publication output [407]
17 Original Research [71, 216, 217, 219, 224, 380, 381,
383–385, 388, 395–398, 403, 404]
14 Review [54, 69, 85, 123, 382, 391, 392, 394, 399,
400, 402, 405–407]
4 Lessons Learned [218, 386, 387, 393]
3 Policy [389, 390, 401]
Africa (3) [391, 400, 405], Developing Countries (7) [54, 69, 85,
123, 382, 392, 406], Middle East/North Africa (1) [399], Ghana
(2) [217, 401], Ivory Coast (1) [224], Kenya (2) [384, 403], Mali
(1) [383], Mozambique (1) [216], Nigeria (6) [386–388, 393, 396,
398], South Africa (11) [71, 218, 219, 381, 385, 390, 394, 395,
402, 404, 407], Sudan (1) [389]















Table 2 Secondary prevention research, n = 208 (Continued)
N = 208 23 Review Article
6 Lessons Learned
6 Policy Papers
Global (3), Africa (9), Developing Countries (11), Middle East/
North Africa (1), Angola (1), Botswana (5), Burkina Faso (6),
Cameroon (7), Congo (9), Egypt (2), Gambia (1), Ghana (8),
Guinea (5), Ivory Coast (3), Kenya (17), Madagascar (1), Malawi
(2), Mali (6), Morocco (1), Mozambique (2), Niger (5), Nigeria
(43), Rwanda (1), South Africa (45), Sudan (2),Tanzania (9),















telemedicine [232] may provide viable methods for pro-
viding cervical cancer screening to HIV-positive women.
Geographically, the countries with the most research
on secondary prevention were South Africa (n = 45),
Nigeria (n = 43), and Kenya (n = 17). Countries were not
evenly represented by category of secondary prevention.
In several cases, a country was well-represented within
one category but not in the others. For example, well
represented in the screening test performance category
were Republic of the Congo (n = 6) Guinea (n = 5), and
Niger (n = 5), yet these countries were not represented
within any of the other categories.
Tertiary prevention
We identified n = 67 articles highlighting aspects of ter-
tiary prevention of cervical cancer in African countries,
reported in Table 3. The primary focus of published
studies and reports included: 7 (10 %) on treatment of
precancerous lesions, 8 (12 %) on diagnosis and staging,
6 (9 %) on treatment for invasive cervical cancer, 8
(12 %) on survival outcomes, 23 (34 %) on HIV and cer-
vical cancer, and 14 (21 %) regarding the feasibility of
providing cervical cancer treatment. Treatment pro-
grams for cervical cancer are limited in most countries
in Africa, as is research contributing outcome data, les-
sons learned, and implementation recommendations.
Late diagnosis was routinely documented in several Afri-
can countries among both HIV+ and HIV-uninfected
women, with the proportion diagnosed with stage III or
higher ranging from 56 to 90 % [87, 88, 233, 234]. Sub-
optimal management of symptomatic patients (in fre-
quent gynecologic exams and appropriate referrals)
further exacerbates the challenge of late diagnosis [234].
The treatment sections for precancerous lesions and in-
vasive cervical cancer are delineated by treatment strategy
to indicate areas receiving more or less research focus.
Studies describing outcomes or evaluating treatment strat-
egies for precancerous lesions included loop electrical
Table 3 Tertiary prevention research, n = 67
Focus Literature type Countries/Geographic Regions Included
Tertiary
Prevention
Treatment of Pre-Cancerous lesions
3 LLETZ [408–410]
2 Cryotherapy [57, 411]
2 Comparison LEEP/Cryotherapy [311, 412]
N = 7
5 Original research [311,
408–411]
2 Review Articles [57, 412]
0 Lessons Learned
0 Policy
Kenya (1) [411], South Africa (3) [408–410],
SSA (2) [57, 412], Nigeria (1) [311]
Late Diagnosis/Staging
N = 8





Nigeria (3) [413–415], Morocco (1) [365],
Tunisia (1) [416], Zimbabwe (1) [233],
Tanzania (1) [88], South Africa (1) [234]
Treatment of Invasive Cervical Cancer
2 Surgery [417, 418]
3 Radiotherapy [419–421]
2 Combination therapy [422, 423]
N = 7
5 Original research [417, 418, 420,
421, 423]
1 Review Articles [422]
1 Lessons Learned [419]
0 Policy
SSA (1) [422], South Africa (3) [418, 420, 423],




6 Original research [87, 95, 100,
424–426]
2 Review Articles [427, 428]
0 Lessons Learned
0 Policy
Malawi (1) [424], Uganda (2) [425, 428],
Gambia (1) [428], Ethiopia (1) [100],
South Africa (1) [426], Zimbabwe (1) [95],
Kenya (1) [87], Egypt (1) [427]
HIV and treatment
8 HIV and CIN [235, 236, 240–242, 244, 429, 430]
8 HIV and ICC [238, 239, 243, 246, 431–434]
7 HIV/Treatment of CIN and ICC [239, 245, 247,
248, 435–437]
N = 23
22 Original research [235, 236,
238–248, 429–433, 435–437]
1 Review Articles [434]
0 Lessons Learned
0 Policy
South Africa (11) [240, 242, 243, 245, 247,
248, 429, 432, 433, 436, 437], Kenya (5)
[235, 236, 239, 244, 430], Uganda (1) [238],
Global/SSA (3) [241, 246, 434], Cote ‘Ivoire
(1) [431], Senegal (1) [435]
Feasibility
1 Access/Awareness/Health Policy [255]
6 Training needs [92, 438–442]
5 Infrastructure needs [443–447]
2 Costs [448, 449]
N = 14
10 Original research
1 Review Articles [445]
0 Lessons Learned
0 Policy Papers
2 Meeting report [92, 442, 447]
1 Book Chapter [255]
Africa (4) [441–443, 447], Kenya (1) [438],
Botswana (1) [444], Nigeria (1) [439], SSA (4)
[92, 255, 445, 446], Morocco (1) [448], Tunisia
(1) [449], South Africa (1) [440]






Kenya (8), South Africa (20), SSA (10),
Nigeria (6), Morocco (2), Tunisia (2),
Zimbabwe (2), Tanzania (1),
Uganda (4), Senegal (2), Malawi (1),
Ethiopia (1), Gambia (1), Egypt (1),
Cote d’Ivoire (1), Botswana (1)
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excision procedure (LEEP) vs cryotherapy (n = 2), large
loop excision of the transformation zone (LEETZ) (n = 3),
and cryotherapy (n = 2). These treatment strategies were
found to be well accepted [235, 236]. Studies regarding
treatment for invasive cervical cancer included surgery (n
= 2), radiotherapy (n = 3) and combined radiochemother-
apy (n = 2). This dearth of research reflects the limited
capacity for cervical cancer treatment in African countries.
According to the African Organization for Research and
Training in Cancer (AORTIC) published in 2013, 22 % of
the 54 countries in Africa have no access to any form of
anti-cancer therapies, which include surgical oncology,
chemotherapy and radiation [237]. Among women who
do begin treatment, loss to follow up continues to be a
problem [61, 238, 239].
The largest proportion of articles was specific to condi-
tions and outcomes of HIV+ women with CIN or cervical
cancer, followed by an emphasis on feasibility consider-
ations for providing treatment. HIV+ women were more
likely to present with CIN or cervical cancer at an earlier
age [240], have higher grade CIN [241, 242], faster pro-
gression [243], more likely to experience CIN reoccur-
rence after treatment [236], and have poorer treatment
and survival outcomes [238, 243, 244]. Antiretroviral ther-
apy was shown to improve treatment outcomes for CIN
and cervical cancer [245–248]. While feasibility articles
were more comprehensive in nature, we categorized them
according to the primary feasibility issue discussed: train-
ing needs of health care personnel on cervical cancer
management (n = 6), the lack of medical infrastructure
and scarcity of equipment to provide treatment (n = 5),
and more generally, issues of access and awareness (n = 1)
and costs (n = 2). While provider training for cervical
cancer screening is slowly improving, multidisciplinary cli-
nicians (pathologist, oncologists, radiologists) for the
treatment of advanced cancer are far too few to meet the
current demand [92, 237]. It’s important to note that
many of the tertiary prevention articles also addressed
feasibility concerns in the discussion sections, but this
subsection reflects articles with a primary focus on
feasibility.
The majority of research on tertiary prevention for cer-
vical cancer was conducted in South Africa and Nigeria,
yet research from countries in West, East and Southern
Africa were also represented. 82 % were original research
articles, 11 % review articles and the remaining 7 % were a
combination of reports and commentary articles.
Quality of life
While there were a significant number of publications
focusing on various aspects of quality of life among cer-
vical cancer patients and survivors in the United States,
Europe, and an increasing number from Taiwan, we
found only n = 16 publications from countries in Africa.
Publications were organized into the following areas of
focus: 8 (50 %) on quality of life (physical, psychological,
emotional, social, and spiritual), 5 (31 %) on palliative
care, 1 (6 %) on partner support, and 2 (13 %) on symp-
toms and complications, see Table 4.
Among the seven publications describing quality of life
outcomes, five studies reported the patient perspective
and 1 study included data from both cervical cancer pa-
tients and caregivers. In regard to the timing of quality
of life assessments, approximately half of these research
studies included patients actively receiving treatment
(typically radiotherapy) and the other half were receiving
Table 4 Quality of life research, n = 16
Focus Literature type Countries/Geographic Regions Included
Quality of Life Quality of Life Outcomes
N = 8
6 Original research [101, 104, 118, 450–452]
2 Review Articles [103, 249]
0 Lessons Learned
0 Policy Papers
South Africa (2) [450, 451], Kenya (1) [104],
Nigeria (2) [101, 118], Sudan (1) [452],
Global-12 world regions (1) [103], Uganda
(3) [249, 450, 451]
Palliative Care
N = 5
3 Original research [250, 252, 253]
1 Review Articles [251]
0 Lessons Learned
1 Policy [117]
Nigeria (1) [250], sub-Saharan Africa (1) [253],








South Africa (1) [108]
Symptoms and complications
N = 2











Global (1), SSA (3), South Africa (4), Kenya (1),
Nigeria (4), Sudan (1), Uganda (5)
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palliative care. A recent review article estimated age-
adjusted, daily-adjusted life years lost attributed to various
types of cancer, including cervical cancer, in sub-Saharan
Africa and other global regions. Five studies focused on
palliative care for cancer patients (specific to or including
cervical cancer patients) in Africa highlighting challenges
to provide adequate pain management [117, 249, 250],
and training to optimize palliative care for cancer patients
[251, 252], including one review article [253]. Only one
study directly addressed partner support for cervical can-
cer patients [108]. One study assessed urologic complica-
tions among women with advanced cervical cancer in
Uganda prior to treatment [254], and another assessed
Cisplatin based chemotherapy for treatment of long term
vaginal bleeding [107]. The majority of these studies was
conducted in Nigeria, South Africa, and Uganda or had a
sub-Saharan Africa regional focus.
Despite the heavy burden of disease and limited access
to cervical cancer treatment, research regarding multiple
quality of life issues for women, their partners, and care-
givers is still limited for countries in Africa. A notable
gap in the literature is attention to fertility-related con-
cerns and the impact of the disease and its treatment on
women’s bodies, sexual function, and relationships.
Distribution of cervical cancer research in Africa
Eligible articles and reports either focused globally (n = 4),
on low or middle income countries (LMIC) (n = 14), the
sub Saharan/African region (n = 27), and targeted multiple
(n = 27) or single (n = 308) countries in Africa. A total of
n = 30 countries in Africa were represented by at least one
publication. Figure 2 illustrates the density of cervical can-
cer research publications by country. This excludes
Fig. 2 Geographic Distribution of Cervical Cancer Research within Africa. Figure 2 is a map of Africa illustrating the geographic distribution of cervical
cancer research. The map represents individual countries only and does not clearly illustrate some of the smaller African countries. Fifty articles reporting
on a geographic region were excluded (Excluded articles reported on the following geographic regions: Middle East/North Africa (2); 3 GAVI-eligible
countries (3); Global (6); LMIC countries/developing countries (14); Africa/Sub-Saharan Africa (25). Image modified from: Tourbillon (Own work) [Public
domain], via Wikimedia Commons, available at https://commons.wikimedia.org/wiki/File:Colored_map_of_Africa.png#
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publications with a regional focus. Five categories ranging
from 0 to >15 publications are delineated by a color gradi-
ent per country.
South Africa had the highest number of cervical cancer
publications included in this review (n = 85), followed by
Nigeria (n = 61), and Uganda and Kenya, with 33 and 32
publications, respectively. These same four countries also
have cervical cancer publications representing each of the
four target categories: primary, secondary, tertiary preven-
tion and quality of life. Botswana, Cote d’Ivoire, Malawi
and Morocco had publications from each of the three
types of prevention, but none related to quality of life.
Eligible cervical cancer publications were missing from a
total of 24 African countries, including: Algeria, Benin,
Burundi, Cape Verde, Central African Republic, Chad,
Comoros, Djibouti, Equatorial Guinea, Eritrea, Gabon,
Guinea-Bissau, Liberia, Libya, Mauritania, Mauritius,
Namibia, Sao Tome and Principe, Seychelles, Sierra
Leone, Somalia, South Sudan, Swaziland, and Togo.
Discussion
This study reviewed cervical cancer related research
from countries in Africa over the past decade and cate-
gorized them according to primary focus areas within
public health. Among a total of 380 research articles/re-
ports eligible for inclusion in this systematic review, the
majority (54.6 %) focused on secondary prevention. The
number of publication focusing on primary prevention
(23.4 %), particularly HPV vaccination, increased signifi-
cantly in the past decade. Research regarding the treat-
ment of precancerous lesions and invasive cervical
cancer are emerging (17.6 %), but infrastructure and
feasibility challenges in many countries have impeded ef-
forts to provide and evaluate such treatment services.
Studies assessing varying aspects of quality of life among
women living with cervical cancer are limited, represent-
ing only 4.1 % of eligible publications. Across all categor-
ies, 11.3 % of publications focused on cervical cancer
prevention or treatment among HIV-infected women.
While integrated throughout, n = 65 (17.1 %) publica-
tions focused on various aspects of feasibility for cervical
cancer control efforts, appealing for increased financial,
human and political investments to adequately address
the existing and increasing need for cervical cancer pre-
vention and treatment services.
Limitations
While a wide range of articles are referenced in the
introduction of this manuscript, the results section of
the review excludes a significant number of articles
describing the epidemiology of cervical cancer in sub
Saharan Africa or a focus on genetic biomarkers, which
were beyond the scope of this review. Some publications
had significant overlap in the topics presented. This was
particularly true for findings on secondary and tertiary
prevention. For the purpose of this review, publications
were assigned to only one category, but this does not
mean other articles or reports did not give a degree of
focus to additional categories as well.
Conclusion
The number of publications focused on cervical cancer
control and treatment in African countries has increased
over the past decade. Tertiary prevention (i.e. treatment of
disease with effective medicine) and quality of life of cer-
vical cancer survivors are two under-researched areas in
African countries. Similarly, there are several countries in
Africa with little to no research ever conducted on cervical
cancer. Given the significant burden and high morbidity
and mortality experienced by women with cervical cancer
in this setting, targeted research is critically needed, par-
ticularly implementation science research to inform feas-
ible and sustainable strategies to maximize the number of
women reached with services. Lessons learned reports and
publications describing and evaluating service implemen-
tation are highly relevant, as are cost-effectiveness studies
to guide service strategies for scale-up. There is a need to
support national capacity for developing population-based
cancer registries to track cases and project needs [255],
strategies to increase the availability of cervical cancer
screening and treatment, and innovative strategies to re-
tain cervical cancer patient in treatment.
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